Xenon Pharmaceuticals (XENE) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.11
- Estimate
- -$1.14
- Surprise
- +3.0%
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Xenon Pharmaceuticals (XENE) reported a narrower loss than forecast — adjusted EPS of -$1.11 against the -$1.14 estimate (a 3.0% beat on a still-unprofitable quarter).
Coverage in the report window
- Xenon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update — fiscal.ai, 2026-11-09
- Xenon Pharmaceuticals Q3 2026 Earnings Call Transcript — benzinga, 2026-11-09
- Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) Estimate — benzinga, 2026-11-09
Where TrendMatrix's rating stands now
TrendMatrix currently rates XENE Sell at 5.6/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +3.0% surprise compares with a +0.3% four-quarter average. Next scheduled report: 2027-03-01.
What argues against it
- Concentration risk — Pipeline: azetukalner
- Quality below floor (1.6 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 4.6), Material insider selling (11 sells, 0.06% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $41.39
- Price target
- $64.58
- Stop
- $38.63
- Upside to target
- +56.0%
- Reward-to-risk
- 3.7:1
Risk check: RSI 75 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-11 — shown for context, not personalized investment advice.
XENE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $4.01B
- P/E (fwd)
- -8.9
- 52-week range
- $33.38–$72.66
- Off 52-week high
- 43.0%
- RSI (14)
- 75
- Volume vs avg
- 1.53×
- Score today
- 5.6/10